Acute Lymphoblastic Leukemia
About
Mappings
NCI Thesaurus: Acute Lymphoblastic Leukemia (coding:ncit:C3167)
OncoTree: B-Lymphoblastic Leukemia/Lymphoma (coding:oncotree:BLL)
OncoTree: T-Lymphoblastic Leukemia/Lymphoma (coding:oncotree:TLL)
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (4) HC (1) | CD19 + | Acute Lymphoblastic Leukemia | Blinatumomab | |
| FDA (2) | CD19 +, not BCR::ABL1 | Acute Lymphoblastic Leukemia | Blinatumomab | |
| FDA (4) HC (1) | BCR::ABL1 | Acute Lymphoblastic Leukemia | Dasatinib | |
| FDA (4) | CD33 + | Acute Lymphoblastic Leukemia | Gemtuzumab ozogamicin | |
| FDA (4) HC (2) | BCR::ABL1 | Acute Lymphoblastic Leukemia | Imatinib | |
| FDA (2) HC (1) | CD22 + | Acute Lymphoblastic Leukemia | Inotuzumab ozogamicin | |
| FDA (2) | BCR::ABL1 | Acute Lymphoblastic Leukemia | Cytarabine, Dexamethasone, Methotrexate, Ponatinib, Prednisone, Vincristine | |
| FDA (2) HC (1) | ABL1 p.T315I, BCR::ABL1 | Acute Lymphoblastic Leukemia | Ponatinib | |
| FDA (2) | t(KMT2A;v) | Acute Lymphoblastic Leukemia | Revumenib |